Bloomberg News

Par Pharmaceutical Sued by Horizon Over Duexis Generic

January 18, 2013

Par Pharmaceutical Cos. was sued for patent infringement by Horizon Pharma Inc. (HNP:US) over a generic version of the drug Duexis, used to treat arthritis.

Horizon, based in Northbrook, Illinois, contends Par plans to market a copy of the drug before two U.S. patents expire in 2026, according to a complaint filed yesterday in federal court in Wilmington, Delaware.

Unless a judge stops the alleged infringement, “Horizon will be irreparably harmed,” the company said in court papers.

Gross sales for Duexis in the third quarter of 2012 were $3 million, Horizon said in a Nov. 13 statement.

Stephen Mock, a spokesman for Woodcliff Lake, New Jersey- based Par, didn’t immediately return a phone call seeking comment on the lawsuit.

The case is Horizon Pharma v. Par Pharmaceutical, U.S. District Court, District of Delaware (Wilmington).

To see the patents in the lawsuit, click: 8,309,127 and 8,318,202.

To contact the reporter on this story: Phil Milford at pmilford@bloomberg.net.

To contact the editor responsible for this story: Michael Hytha at mhytha@bloomberg.net


American Apparel's Future
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

Companies Mentioned

  • HNP
    (Huaneng Power International Inc)
    • $47.0 USD
    • 1.50
    • 3.19%
Market data is delayed at least 15 minutes.
 
blog comments powered by Disqus